OncLive Staff

Articles

Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma

March 2nd 2023

Dr Jakubowiak discusses interim findings from the ATLAS trial of lenalidomide plus carfilzomib and dexamethasone vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma, contextualizes these data within the broader post-transplant landscape, and previews the next steps for this research.

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

Dr Leslie discusses the FDA approval of pirtobrutinib in patients with MCL previously treated with a BTK inhibitor, key efficacy and safety findings from the BRUIN trial, and potential treatment sequencing strategies in patients with resistance to covalent BTK inhibitors.

Finding and Leveraging CEACAM5 Presents Opportunities and Pitfalls

February 24th 2023

As carcinoembryonic antigen–related cell adhesion molecule 5 continues to show promise a target in patients with non–small cell lung cancer, refinements in testing and the understanding of the implications of its inhibition remain under investigation.

Mascarenhas Summarizes Therapeutic Standards and Advances in Myelofibrosis Management

February 23rd 2023

Dr Mascarenhas discusses established standards of care and ongoing research with JAK inhibitors in patients with myelofibrosis; the available frontline treatment options in this disease; and the nuances of myelofibrosis treatment sequencing.

Camidge and Bauml on Breaking Into Industry From Academia

February 20th 2023

In this episode of ‘How This is Building Me,’ Camidge sits down with Bauml to discuss the transition from academia to industry, reasons for the move, expectations for the future, and more.

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

Drs Flinn, Lamanna, Brown, and Tam discuss the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

EPCORE Pushes CD3 × CD20 Bispecific Antibody Into Next Phase of Exploration in DLBCL

February 15th 2023

Advances in the development of bispecific antibodies have demonstrated response rates close to or surpassing those of other agents in development, offering investigators an avenue to pursue phase 3 studies such as EPCORE DLBCL-1 to challenge standard of care with the CD3 × CD20 agent, epcoritamab in diffuse large B-cell lymphoma.

2023 Cancer Trends Highlight Opportunities to Close Gaps in Care in Community Practice

February 14th 2023

A renewed focus on dismantling the barriers and closing gaps in care will aid in the mission to drive down the rate of cancer mortality and incidence across disease states.

Small and Reagan Review Tumor Lysis Syndrome Risk Factors and Management Strategies

February 13th 2023

Drs Short and Reagan discuss risk factors that can contribute to patients’ likelihood of developing tumor lysis syndrome, preventive measures for patients most at risk, and the clinical implications of standard treatment options for patients with tumor lysis syndrome.

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023

Dr D’Amato discusses research in sarcoma and gastrointestinal stromal tumor, incorporating circulating tumor DNA analysis into routine reevaluation of patients with progressive disease, and the importance of establishing a drug’s clinical profile in non–trial target ethnic populations.

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023

Dr Strickler discusses the FDA approval of tucatinib plus trastuzumab in metastatic colorectal cancer, key efficacy and safety findings from the MOUNTAINEER trial, and ongoing research seeking to address remaining unmet needs in this population.

Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma

February 2nd 2023

Dr Rosenthal discusses the care of adolescent and young adult patients with Hodgkin lymphoma, the discrepancies between pediatric and adult oncologists that result in differing treatment approaches, and common concerns these patients have as they navigate their diagnosis and treatment alongside other life changes.

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

Dr Nair discusses a study evaluating the role of yoga as a complementary therapy in patients with breast cancer, how these results emphasize the importance of multidisciplinary breast cancer care, and the potential applications of these findings beyond breast cancer.

Further Study and Tailored Treatments Remain Unmet Needs in Male Breast Cancer

January 30th 2023

Jose Pablo Leone, MD, discusses the distinguishing features of male breast cancer, explains the benefits and limitations of current treatments, and emphasizes the importance of raising awareness about this breast cancer subset to propel further research.

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

Dr Shore discusses the FDA approval of nadofaragene firadenovec in non–muscle invasive bladder cancer, the benefits of this therapy’s administration method and schedule, and how this agent’s efficacy and safety pave the way for future treatment advances.

Practices Should Redouble Efforts to Help Patients Address Financial Toxicity

January 25th 2023

Although fully addressing the financial hardship of patients with cancer requires a complex, multifaceted approach, even small changes may ease these burdens and improve patient outcomes.

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

Drs Goetz and Choong discuss the potential for adjuvant endocrine therapy omission in patients with estrogen receptor–positive breast cancer who have a pathologic complete response to neoadjuvant chemotherapy.

Experts Contextualize ASH Findings for Clinical Practice

January 23rd 2023

Data presented during the 2022 ASH Annual Meeting and Exposition showcased practice-changing updates from several studies across hematologic malignancies. Experts across hematologic cancers were on hand to discuss long-term readouts, the introduction of novel regimens for several diseases, and the impact of new data and trends in care for patients.

Dy Discusses CEACAM5-Directed and Other Second-Line Treatment Strategies in NSCLC

January 19th 2023

Dr Dy discusses the development of CEACAM5-directed antibody-drug conjugates in non–small cell lung cancer, ongoing research with tusamitamab ravtansine, and the potential role of competing docetaxel-based combination strategies in the second-line setting.

Giacchetti Discusses the Convergence of Chronobiology and Oncologic Care in Breast Cancer

January 16th 2023

Dr Giacchetti discusses the findings from a study of patient-selected timing of the daily oral intake of adjuvant hormone therapy and everolimus in breast cancer and how this study highlights the need for further research combining the fields of chronobiology and oncology.